Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants
NCT ID: NCT05630326
Last Updated: 2023-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5600 participants
OBSERVATIONAL
2023-03-01
2023-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Efficacy on the 5th Day of Antibiotic Therapy for Febrile Urinary Tract Infections Among Children From 3 Months to 18 Years Old
NCT04667546
Urinary Tract Infection in Pregnancy
NCT04244526
Management of Sub-Clinical Bacteriuria in Pregnancy
NCT03275623
a Smptomatic Bacteriuria in Pregnancy
NCT03499561
Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department
NCT04583189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESBL UTI
all infants with UTIs caused by ESBL producing organisms
comparing, prevalence
Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
Non-ESBL UTI
all infants with UTIs caused by non-ESBL producing organisms
assessment
comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
ESBL UTI with COVID-19
all infants with UTIs caused by ESBL producing organisms with COVID-19 infection
association
comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
ESBL UTI without COVID-19
all infants with UTIs caused by ESBL producing organisms without COVID-19 infection
evaluation
comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
comparing, prevalence
Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
assessment
comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
association
comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
evaluation
comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hamad Medical Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mahmoud Alhandi Omar Helal
Role: PRINCIPAL_INVESTIGATOR
Hamad Medical Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hamad Medical Corporation
Doha, , Qatar
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRC-01-22-158
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.